Company Overview of Spear Therapeutics Ltd.
Spear Therapeutics Ltd. develops prodrugs for the treatment of cancer. It offers cytochrome P450 (CYP)-activated prodrugs, which include aromatic hydroxylation activators, nitric/nitrogen oxide release agents, and compounds possessing specific CYP enzyme-activated drug release activity. The company was incorporated in 2002 and is based in London, United Kingdom. As of January 28, 2015, Spear Therapeutics Ltd. operates as a subsidiary of Incanthera Ltd.
London, WC2 A3PF
Founded in 2002
Key Executives for Spear Therapeutics Ltd.
Similar Private Companies By Industry
|Abbey Pharma Limited||Europe|
|Absynth Biologics Limited||Europe|
|Acacia Pharma Limited||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Spear Therapeutics Ltd., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.